Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients With Severe Haemophilia A
Phase: PHASE3
Conditions: Congenital Bleeding Disorder, Haemophilia A
Sponsor: Novo Nordisk A/S

	
	

			
432835B2!1%B
3>3B35$+8.BB
 2<1"%5B
 
B
432835B95+!/BB
	B
(-#+!/B9+9/%B3&B89<$AB
!&%9AB!2$B(-#!#AB3&B;=63#:3#3)B!0'B4%)3/BB,2B
734*A/!@,8B!2$B 5%!91%29B3&B/%%$8B+2B5%>+3<8/ABB
 5%!9%$B!:+%298B?+9*B%>%5%B!%134*+/+!BB
3#<1%29B$!9%
B
B<2%B

!,*0*0&)0*!0+0*0!0.0+0!,*0.'0!(*0&+/0,#*
!*0
0*00*0&0"0	00(0+0*0!0!$*!0!0*0!-*(00 !*0!00,%*0*!0!**